Chantal Csajka

List of Publications by Year
in descending order

113 papers	3,841 citations	126858 33 h-index	143943 57 g-index
118 all docs	118 docs citations	118 times ranked	5453 citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients. Clinical Cancer Research, 2004, 10, 3728-3736.	3.2	403
2	Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics, 2003, 73, 20-30.	2.3	231
3	Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokineticsâ€"Based Analysis of Adult Patients With Invasive Fungal Infections. Clinical Infectious Diseases, 2012, 55, 381-390.	2.9	178
4	Pharmacokineticâ€"Pharmacodynamic Modelling: History and Perspectives. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 227-279.	0.8	147
5	Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools. Clinical Pharmacokinetics, 2013, 52, 9-22.	1.6	141
6	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and Genomics, 2009, 19, 300-309.	0.7	133
7	Gender medicine and oncology: report and consensus of an ESMO workshop. Annals of Oncology, 2019, 30, 1914-1924.	0.6	120
8	Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals. Clinical Pharmacology and Therapeutics, 2009, 85, 485-494.	2.3	113
9	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics, 2010, 20, 217-230.	0.7	104
10	Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology. Journal of Clinical Oncology, 2018, 36, 2680-2683.	0.8	100
11	Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection. Antimicrobial Agents and Chemotherapy, 2006, 50, 3801-3808.	1.4	82
12	Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. Scientific Reports, 2019, 9, 5078.	1.6	71
13	Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. Journal of Clinical Pharmacology, 2016, 56, 909-935.	1.0	61
14	The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib. Frontiers in Pharmacology, 2020, 11, 177.	1.6	59
15	Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and N-Acetyltransferase 2 Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania. Antimicrobial Agents and Chemotherapy, 2013, 57, 950-958.	1.4	51
16	Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. British Journal of Clinical Pharmacology, 2014, 78, 1090-1101.	1.1	50
17	Pregnancy Outcome Following Exposure to Topical Retinoids: A Multicenter Prospective Study. Journal of Clinical Pharmacology, 2012, 52, 1844-1851.	1.0	48
18	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. Expert Opinion on Drug Safety, 2015, 14, 413-427.	1.0	47

#	Article	IF	Citations
19	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence â€" an update. Expert Opinion on Drug Safety, 2019, 18, 949-963.	1.0	47
20	Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. European Journal of Clinical Pharmacology, 2021, 77, 147-162.	0.8	47
21	Population pharmacokinetic approach to evaluate the effect of *CYP2D6*, *CYP3A*, *ABCB1*, *POR* and *NR1I2* genotypes on donepezil clearance. British Journal of Clinical Pharmacology, 2014, 78, 135-144.	1.1	46
22	Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clinical Pharmacokinetics, 2015, 54, 1259-1272.	1.6	44
23	Therapeutic Drug Monitoring of Imatinib. Clinical Pharmacokinetics, 2012, 51, 187-201.	1.6	43
24	Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors. Clinical Pharmacokinetics, 2013, 52, 211-223.	1.6	41
25	Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels. Pharmacogenetics and Genomics, 2013, 23, 84-93.	0.7	41
26	Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. Journal of Antimicrobial Chemotherapy, 2018, 73, 3413-3422.	1.3	40
27	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. Antimicrobial Agents and Chemotherapy, 2012, 56, 2959-2966.	1.4	39
28	Polypharmacy, Drugâ€"Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. Open Forum Infectious Diseases, 2019, 6, ofz531.	0.4	38
29	Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Current HIV/AIDS Reports, 2006, 3, 118-125.	1.1	37
30	Population Pharmacokinetics and Clinical Response for Artemether-Lumefantrine in Pregnant and Nonpregnant Women with Uncomplicated Plasmodium falciparum Malaria in Tanzania. Antimicrobial Agents and Chemotherapy, 2014, 58, 4583-4592.	1.4	37
31	Large-scale imatinib doseâ€"concentrationâ€"effect study in CML patients under routine care conditions. Leukemia Research, 2014, 38, 764-772.	0.4	37
32	Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus. Antimicrobial Agents and Chemotherapy, 2004, 48, 3226-3232.	1.4	36
33	Systematic Review of Population Pharmacokinetic Analyses of Imatinib and Relationships With Treatment Outcomes. Therapeutic Drug Monitoring, 2013, 35, 150-167.	1.0	36
34	Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. British Journal of Clinical Pharmacology, 2018, 84, 568-578.	1.1	35
35	Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology. Analytical and Bioanalytical Chemistry, 2014, 406, 2627-2640.	1.9	34
36	Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Malaria Journal, 2013, 12, 235.	0.8	33

#	Article	IF	Citations
37	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. British Journal of Clinical Pharmacology, 2013, 75, 1007-1018.	1.1	33
38	Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	32
39	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2014, 69, 2489-2498.	1.3	31
40	Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 124-136.	1.2	31
41	Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clinical Pharmacokinetics, 2018, 57, 1-6.	1.6	29
42	The Use of a Sum of Inverse Gaussian Functions to Describe the Absorption Profile of Drugs Exhibiting Complex Absorption. Pharmaceutical Research, 2005, 22, 1227-1235.	1.7	27
43	Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations. Therapeutic Drug Monitoring, 2013, 35, 270-275.	1.0	27
44	High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate. Journal of Chromatography A, 2014, 1369, 52-63.	1.8	26
45	Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. Clinical Pharmacokinetics, 2016, 55, 1521-1533.	1.6	25
46	Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	25
47	Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacological Research, 2020, 154, 104278.	3.1	25
48	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Therapeutic Drug Monitoring, 2020, 42, 33-44.	1.0	25
49	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenetics and Genomics, 2013, 23, 9-18.	0.7	25
50	Therapeutic drug monitoring of targeted anticancer therapy. Biomarkers in Medicine, 2015, 9, 887-893.	0.6	24
51	Population pharmacokinetics of dolutegravir: influence of drug–drug interactions in a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 2690-2697.	1.3	23
52	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. Antimicrobial Agents and Chemotherapy, 2013, 57, 3147-3158.	1.4	22
53	Development and validation of a multiplex UHPLC–MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. Journal of Mass Spectrometry, 2020, 55, e4506.	0.7	22
54	Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. Clinical Pharmacokinetics, 2018, 57, 229-242.	1.6	21

#	Article	IF	Citations
55	Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. PLoS ONE, 2012, 7, e29186.	1.1	21
56	Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. European Journal of Clinical Pharmacology, 2001, 57, 723-727.	0.8	20
57	Risk perception by healthcare professionals related to drug use during pregnancy: a Swiss survey. Swiss Medical Weekly, 2014, 144, w13936.	0.8	20
58	ADME pathway approach for pharmacogenetic studies of anti-HIV therapy. Pharmacogenomics, 2007, 8, 623-633.	0.6	19
59	Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1057, 101-109.	1.2	19
60	Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers. Clinical Pharmacokinetics, 2002, 41, 137-152.	1.6	18
61	Cross-cultural adaptation and psychometric validation of the revised Patientsâ€™ Attitudes Towards Deprescribing (rPATD) questionnaire in French. Research in Social and Administrative Pharmacy, 2021, 17, 1453-1462.	1.5	17
62	Parametric Approaches in Population Pharmacokinetics. Journal of Clinical Pharmacology, 2022, 62, 125-141.	1.0	17
63	Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy. PLoS ONE, 2011, 6, e18578.	1.1	16
64	Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 131, 233-245.	1.4	16
65	Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 609-622.	1.5	15
66	Protocols for cognitive enhancement. A user manual for Brain Health Servicesâ€"part 5 of 6. Alzheimer's Research and Therapy, 2021, 13, 172.	3.0	15
67	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 71, 1933-1942.	1.3	13
68	A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk. British Journal of Clinical Pharmacology, 2020, 86, 1642-1653.	1.1	13
69	Population Pharmacokinetics of Erlotinib in Patients With Nonâ€"small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. Clinical Therapeutics, 2020, 42, 1302-1316.	1.1	13
70	Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians. American Journal of Medicine, 2021, 134, 939-942.	0.6	13
71	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. Cancers, 2020, 12, 931.	1.7	12
72	Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.. Experimental and Clinical Psychopharmacology, 2017, 25, 353-362.	1.3	12

#	Article	IF	Citations
73	Safety of Drugs during Pregnancy and Breastfeeding in Cystic Fibrosis Patients. Respiration, 2016, 91, 333-348.	1.2	11
74	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. Clinical Mass Spectrometry, 2018, 8, 8-20.	1.9	10
75	UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1125, 121733.	1.2	10
76	Population pharmacokinetics and pharmacodynamics of the artesunateâ€"mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children. Malaria Journal, 2019, 18, 139.	0.8	10
77	Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	9
78	Parametric and Nonparametric Methods in Population Pharmacokinetics: Expertsâ€™ Discussion on Use, Strengths, and Limitations. Journal of Clinical Pharmacology, 2022, 62, 158-170.	1.0	9
79	Dosage Optimization of Treatments Using Population Pharmacokinetic Modeling and Simulation. Chimia, 2012, 66, 291-295.	0.3	8
80	Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. Clinical Pharmacokinetics, 2020, 59, 371-382.	1.6	8
81	Tobramycin exposure from active calcium sulfate bone graft substitute. BMC Pharmacology & Toxicology, 2014, 15, 12.	1.0	7
82	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drugâ€"drug interactions and probability of target attainment. British Journal of Clinical Pharmacology, 2019, 85, 2022-2032.	1.1	7
83	Contribution of Genetic Background and Data Collection on Adverse Events of Antiâ€"human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. Clinical Infectious Diseases, 2019, 70, 890-897.	2.9	7
84	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. Open Forum Infectious Diseases, 2020, 7, ofz464.	0.4	7
85	Clinical and economic impacts of explicit tools detecting prescribing errors: A systematic review. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 877-886.	0.7	7
86	Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data. JMIR Research Protocols, 2021, 10, e30090.	0.5	7
87	High anticholinergic burden at admission associated with inâ€"hospital mortality in older patients: A comparison of 19 different anticholinergic burden scales. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 288-300.	1.2	7
88	Pharmacometrics-based decision tools facilitate mHealth implementation. Expert Review of Clinical Pharmacology, 2017, 10, 39-46.	1.3	6
89	Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. Clinical Pharmacokinetics, 2019, 58, 1517-1532.	1.6	6
90	Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration. European Journal of Clinical Pharmacology, 2021, 77, 1169-1180.	0.8	6

#	Article	IF	Citations
91	Evaluation of the association of anticholinergic burden and delirium in older hospitalised patients â€" A cohort study comparing 19 anticholinergic burden scales. British Journal of Clinical Pharmacology, 2022, 88, 4915-4927.	1.1	6
92	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. Antiviral Therapy, 2015, 20, 261-269.	0.6	5
93	Influence of Drugâ€"Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Clinical Pharmacokinetics, 2020, 59, 1037-1048.	1.6	5
94	Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. Clinical Pharmacology and Therapeutics, 2022, 112, 353-363.	2.3	5
95	Outbreak in meldonium positive laboratory tests: are we missing something?. British Journal of Sports Medicine, 2016, 50, 1422-1423.	3.1	4
96	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. Clinical Pharmacokinetics, 2021, 60, 379-390.	1.6	4
97	Ability to detect potentially inappropriate prescribing in older patients: comparative analysis between PIM-Check and STOPP/STARTv2. European Journal of Clinical Pharmacology, 2021, 77, 1747-1756.	0.8	4
98	Impact of Pharmaceutical Interventions in Hospitalized Patients: A Comparative Study Between Clinical Pharmacists and an Explicit Criteria-Based Tool. Current Therapeutic Research, 2021, 95, 100650.	0.5	4
99	Mechanistic Pharmacokinetic and Pharmacodynamic Modeling of CHF3381 (2-[(2,3-Dihydro-1H-inden-2-yl)amino]acetamide Monohydrochloride), a Novel N-Methyl-d-aspartate Antagonist and Monoamine Oxidase-A Inhibitor in Healthy Subjects. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 647-657.	1.3	3
100	Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model. Journal of Antimicrobial Chemotherapy, 2013, 68, 1635-1641.	1.3	3
101	Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. Journal of Antimicrobial Chemotherapy, 2019, 74, 2468-2470.	1.3	3
102	Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial. PLoS ONE, 2019, 14, e0210789.	1.1	3
103	Reply to L. Pala et al. Journal of Clinical Oncology, 2019, 37, 439-440.	0.8	3
104	Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer. Pharmaceutics, 2022, 14, 1317.	2.0	3
105	Improved Investigations in Drug Safety by More In-Depth Individual Pharmacokinetics Using High-Resolution Mass Spectrometry. Therapeutic Drug Monitoring, 2015, 37, 141-146.	1.0	2
106	Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. Therapeutic Drug Monitoring, 2016, 38, 506-515.	1.0	2
107	Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. European Journal of Clinical Pharmacology, 2019, 75, 939-949.	0.8	2
108	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. European Journal of Clinical Pharmacology, 2021, 77, 979-987.	0.8	2

#	Article	IF	Citations
109	Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective. , 2012, , 197-250.		2
110	Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. Journal of Antimicrobial Chemotherapy, 2021, , .	1.3	2
111	Utility of an Algorithm to Increase the Accuracy of Medication History in an Obstetrical Setting. PLoS ONE, 2016, 11, e0151205.	1.1	1
112	Interventions to support adherence to oral anticancer therapies: research challenges, lessons learned, and strategies to overcome them from Australia and Switzerland. Supportive Care in Cancer, 2022, 30, 3655-3659.	1.0	1
113	Pratique de la pharmacie clinique en Suisse romande. , 2018, , 1141-1152.e3.		0